Clinical trials: Magnesium Deficiency
HIV Infections
A Pharmacokinetic Study to Evaluate the Effect of MAALOX on Raltegravir (MK-0518) in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-295)
This study evaluated the effect of single doses of a magnesium/aluminum antacid (MAALOX) given 4 and 6 hours before or after administration of raltegravir, on the pharmacokinetics of raltegravir in human immunodeficiency virus…
- Trial name
- NCT01930045
- Testing
- Raltegravir (ISENTRESS™), MAALOX (MAL)
- Volunteers
- 18 people
- Sponsor
- Merck Sharp & Dohme LLC